In gastrointestinal stromal tumors (GISTs), mutually exclusive gain-of-function mutations of KIT and PDGFRA are associated with different mutation-dependent clinical behavior. Taking into account the well-known different clinical behavior of GISTs from the stomach or the intestine, the aim of the current study is to evaluate the mutation-and site-dependent effects on mRNA and protein expression of KIT and PDGFRA in a large series of primary GISTs. Fresh-frozen tissue of 53 primary GISTs from gastric (75%) or intestinal (25%) sites were analyzed for mutation of KIT or PDGFRA using direct sequencing. Furthermore, KIT and PDGFRA mRNA and protein expression were determined using quantitative RT-PCR and quantitative densitometric evaluation of Western blot data. Each tumor either had a mutation of KIT (79%) or PDGFRA (21%). All GISTs with PDGFRA mutation were from gastric sites. Mutation-dependently, GISTs with KIT mutation had a significantly higher expression of KIT and at the same time a significantly lower expression of PDGFRA compared to GISTs with PDGFRA mutation. Site-dependently, gastric GISTs had a significantly higher expression of PDGFRA and a significantly lower expression of KIT compared to intestinal GISTs. Additionally, even if the KIT-mutated GISTs alone were considered, a significantly higher expression of PDGFRA could be observed in gastric than in intestinal tumors. We also found a significant correlation between a higher protein expression of PDGFRA and longer disease-free survival. The correlation of gastric site and PDGFRA mutation with higher PDGFRA expression and longer disease-free survival suggests different regulatory roles of KIT and PDGFRA gene expression on the control of cell proliferation, and, thereby on clinical behavior. The higher PDGFRA expression in gastric GISTs possibly contributes to the well-known site-dependent clinical behavior.
Gain-of-function mutations of the type III receptor tyrosine kinases KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) and PDGFRA (platelet-derived growth factor receptor, a polypeptide) have been identified as the central event in the tumorigenesis of gastrointestinal stromal tumors (GISTs). 1, 2 The interstitial cells of Cajal located in the muscular layer of the gastrointestinal tract are regarded as the precursor cells for GISTs, 3 and ligand-independent constitutive receptor tyrosine kinase signaling presumably initiates neoplastic formation in interstitial cells of Cajal through elevated cell proliferation. 4 Mutations of KIT and PDGFRA have been demonstrated to occur mutually exclusively. About 60-70% of GISTs have activating mutations of KIT, whereas mutations of PDGFRA are less frequent and can be found in only 10-20% of GISTs. [5] [6] [7] [8] [9] GISTs with KIT mutation and PDGFRA mutation are characterized by distinct histomorphologic phenotypes, and GISTs with PDGFRA mutation appear clinically less aggressive. [9] [10] [11] [12] [13] [14] [15] Two similar studies analyzing gene expression in GISTs with KIT or PDGFRA mutation reported that the mRNA and protein expression of KIT and PDGFRA are highly different between these two types of tumors. 16, 17 Although both genes were basically expressed in all tumors, the quantitative regulation was different, in that tumors with KIT mutation had a higher expression of KIT, whereas the tumors with PDGFRA mutation had a higher expression of PDGFRA. These findings suggest an important impact of the activating mutation on the expression of the mutated gene itself, providing a possible explanation for mutation-dependent differences in clinical behavior.
It has also been observed that GISTs from the intestine generally exhibit a more aggressive clinical course compared to GISTs from the stomach. 18, 19 Correspondingly, Antonescu et al 20 found an anatomical site-dependent gene expression in GISTs, and PDGFRA was among the genes that were expressed higher in the gastric tumors.
The aim of the current study was to determine the mRNA and protein expression of KIT and PDGFRA in a large series of 53 primary GISTs with mutation of KIT or PDGFRA from different anatomical sites, to evaluate quantitatively site-dependent differences in the expression levels of KIT and PDGFRA. Furthermore, we compared the impact of mutated gene, anatomical site and gene expression on the clinical behavior, to determine whether the expression of KIT and PDGFRA would be a valuable independent factor for the prognosis of GISTs.
Materials and methods

Tumor Samples
This study comprises both snap-frozen as well as formalin-fixed and paraffin-embedded tissue samples from 53 primary GISTs. All tumors were removed surgically without other prior treatment. None of the patients (Table 1) had received imatinib mesylate (Gleevec, Novartis, Switzerland) before operation or disease progression. No adjuvant treatment has been carried out. Mitoses were counted in 50 high-power fields (HPFs), while proliferation rate was estimated as the percentage of Mib1-positive nuclei from tumor areas with the highest mitotic activity. Risk of clinically aggressive behavior was evaluated according to the consensus approach published by Fletcher et al, 21 and the malignant potential was evaluated according to the proposal of Miettinen et al.
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Mutation Analysis of KIT and PDGFRA Genes Mutation analysis of KIT exons 9, 11, 13 and 17, as well as PDGFRA exons 12, 14 and 18 was performed on snap-frozen tumor tissue from all 53 primary GISTs using direct sequencing of PCR products as described previously. 23 
RNA Isolation and Reverse Transcription
Total RNA was isolated from snap-frozen tumor tissue from all 53 GISTs using B50 mg frozen tissue per ml TRIzol (Invitrogen Life Technologies, Karlsruhe, Germany) as described previously. 23 Total RNA concentration was quantified with the RNA 6000 nano LabChip using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).
Quantitative PCR
Gene specific primers for KIT (5 0 -ATGTTGTCCCAA CCAAGG-3 0 and 5 0 -CTTCTAAGTCTAGGGCCAAC TC-3 0 ) and PDGFRA (5 0 -TGTCCTGGTTGTCATTTG GA-3 0 and 5 0 -CTTCAACCACCTTCCCAAAC-3 0 ) were designed on different exons with a melting temperature of 601C for PCR products with a length of 114 and 200 nucleotide pairs, respectively. PCR was run in 20 ml reactions in triplicates on an iCycler (Bio-Rad Laboratories GmbH, Mü nchen, Germany) using the QuantiTect SYBR Green PCR Kit (Qiagen, Hilden, Germany) and gene-specific primers in a final concentration of 300 nM. The temperature profile consisted of (i) an initial step at 951C for 10 s for Taq activation; (ii) 40 cycles at 951C for 15 s and 601C for 60 s; and (iii) a final melting curve analysis with a temperature ramp from 60 to 951C and a heating rate of 31C/min. PCR efficiencies were calculated with a relative standard curve derived from a cDNA mixture (a twofold dilution series with seven measuring points in triplicates) and gave regression coefficients 40.95 and reproducible primer-specific efficiencies of 85-99%. Gene-specific amplification was confirmed by a single peak in melting curve analysis and a single band in highresolution agarose gel electrophoresis (SeaKem LE agarose, BMA Rockland, ME, USA). No template controls (no cDNA in PCR) and genomic controls (no enzyme in reverse transcription reaction) were run for each gene to detect unspecific and genomic amplification or primer dimerization. Relative expression levels were calculated from the relative standard curve. 24 The reference genes 18S rRNA and actin beta (ACTB) could be confirmed to be equivalently expressed within most of the examined groups as described previously. 25 Expression of KIT and PDGFRA mRNA was calculated in relation to the mean expression of 18S and ACTB, and logarithmized to obtain approximately normally distributed data. The fold-change comparisons for the expression of KIT and PDGFRA between different groups were calculated as the ratio between the means.
SDS-PAGE and Western Blot Analysis
Total lysates of 49 snap-frozen tumor tissues were separated on 10 or 12% SDS-polyacrylamide gels (SDS-PAGE), and the proteins were electrophoretically Site-dependent KIT and PDGFRA expression 
Statistics
Descriptive statistics, tests and graphs were performed with Statistica 6.0 (StatSoft, Hamburg, Germany), and the statistical software system R.
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Associations between the clinicopathological and the molecular genetic parameters were evaluated using the Wilcoxon test or the Fisher test in the case of categorical variables. Disease-free survival rates were plotted by the Kaplan-Meier method. Associations of patient and tumor parameters with diseasefree survival times were assessed using the log-rank test.
Results
Clinicopathologic Analysis and Disease-Free Survival
The current study comprised 53 primary GISTs, including 40 (75%) from gastric and 13 (25%) from intestinal sites (Table 1) . Mutation analysis revealed KIT mutation in 42 (79%) cases and PDGFRA mutation in 11 (21%) cases. No cases were observed with both KIT and PDGFRA mutation. All 11 cases with PDGFRA mutation were from gastric sites, while 29 (69%) and 13 (31%) of the cases with KIT mutation were from gastric and intestinal sites, respectively (P ¼ 0.03). Six (11%) patients had synchronous metastatic disease at the time of operation. Seven (13%) patients developed metachronous progressive disease after a mean of 33 months (range: 13-84 months). Forty (75%) patients had no disease progression after a mean follow-up of 44 months (range: 8-112 months). Patients with gastric tumors had significantly longer disease-free survival than patients with intestinal tumors (P ¼ 0.004), and patients with PDGFRA-mutated tumors had a significantly longer disease-free survival than patients with KIT-mutated tumors (P ¼ 0.04). Additionally, KIT-mutated tumors from gastric sites were associated with significantly longer disease-free survival compared to KIT-mutated tumors from intestinal sites (P ¼ 0.03, Figure  1 ). On the other hand, there was no significant difference in disease-free survival when comparing gastric tumors with PDGFRA and KIT mutation.
Mutation-Dependent Expression of KIT and PDGFRA
The mean KIT expression was 10.3-fold higher on the mRNA level (P ¼ 6 Â 10 À7 ) and 7.5-fold higher on the protein level (P ¼ 0.03) in both gastric and intestinal GISTs with KIT mutation compared to GISTs with PDGFRA mutation (Figure 2a and b) . On the other hand, the mean PDGFRA expression was 7.3-fold lower on the mRNA level (P ¼ 5 Â 10 À4 ) and 25.7-fold lower on the protein level (P ¼ 0.001) in GISTs with KIT mutation (Figure 2c and d) .
Site-Dependent Expression of KIT and PDGFRA
In addition to the mutation-dependent expression of KIT and PDGFRA, the expression of these two genes was also site-dependent. The mean PDGFRA expression was significantly higher in gastric GISTs compared to their intestinal counterparts (8.2-fold higher on the mRNA level, P ¼ 8 Â 10 À4 ; and 86.2-fold higher on the protein level, P ¼ 3 Â 10 À5 , Figure  3a and b). In contrast, the mean KIT expression was significantly lower in gastric GISTs (2.6-fold lower KIT mutation intestinal KIT mutation gastric PDGFRA mutation Probability for disease-free survival Figure 1 Mutation-and site-dependent differences in disease-free survival. PDGFRA-mutated GISTs were exclusively from gastric sites, and none of these patients had tumor progress. Patients with gastric KIT-mutated tumors had significantly longer disease-free survival compared to patients with intestinal KIT-mutated tumors (P ¼ 0.03). There was no statistically significant difference in disease-free survival for patients with PDGFRA-mutated tumors and gastric KIT-mutated tumors.
Site-dependent KIT and PDGFRA expression F Haller et al on the mRNA level, P ¼ 0.02; and 5.3-fold lower on the protein level, P ¼ 0.006, Figure 3c and d). This mutation-independent but site-dependent difference was even more obvious when only KITmutated GISTs from gastric and intestinal sites were compared. Gastric GISTs with KIT mutation expressed PDGFRA 5.5-fold higher on the mRNA level (P ¼ 0.008) and 52.2-fold higher on the protein level (P ¼ 2 Â 10 À4 ) compared to their intestinal counterparts with KIT mutation (Figure 4a and b) . On the other hand, although the mean mRNA expression of KIT was not significantly different between gastric and intestinal GISTs with KIT mutation (Figure 4c) , the mean protein expression of KIT was 3.7-fold lower in gastric GISTs with KIT mutation compared to intestinal GISTs with KIT mutation (P ¼ 0.02, Figure 4d ). The comparison of mutation-dependent and site-dependent regulation of KIT and PDGFRA expression revealed that the regulation of PDGFRA expression was equally mutation-and site-dependent, whereas the regulation of KIT expression was rather mutation-dependent (Figure 4) .
Expression of PDGFRA and Disease-Free Survival
A significantly higher mean expression of PDGFRA was detected in the 40 GISTs without tumor progress than in the 13 GISTs with tumor progress (2.8-fold higher on the mRNA level, P ¼ 0.06 and 27.3-fold higher on the protein level, P ¼ 0.002). Correspondingly, a two-sided group-wise comparison of tumors with high vs low PDGFRA protein expression separated by the mean revealed that higher PDGFRA protein expression significantly correlated with longer disease-free survival (P ¼ 0.01, Figure 5 ).
Discussion
Apart from the previously described mutationdependent expression of KIT and PDGFRA, 16, 17 we report here on a site-dependent expression of KIT and PDGFRA. Gastric GISTs had a 8.2-fold higher mRNA expression and a 86.2-fold higher protein expression of PDGFRA compared to GISTs from the Site-dependent KIT and PDGFRA expression F Haller et al intestine. Furthermore, gastric GISTs had a 2.6-fold lower mRNA expression and a 5.3-fold lower protein expression of KIT compared to intestinal GISTs. As PDGFRA mutations were found exclusively in gastric GISTs, we performed a subgroup analysis among KIT-mutated GISTs to preclude a mutation-dependent bias. This analysis confirmed a further mutation-independent correlation between higher KIT expression and intestinal tumor site, and higher PDGFRA expression and gastric tumor site. Gastric GISTs with KIT mutation had a 5.5-fold higher mRNA expression and a 52.2-fold higher protein expression of PDGFRA compared to intestinal GISTs with KIT mutation. On the other hand, intestinal GISTs had a 3.7-fold higher protein expression of KIT. Therefore, a site-dependent constitutional difference in the expression of KIT and PDGFRA exists and is maintained irrespective of the type of activating mutation that may occur. This new finding of a different site-dependent expression of KIT and PDGFRA is of further relevance for understanding the site-dependent differences in the clinical behavior of GISTs. Tumor site is an independent prognostic parameter in GISTs, with intestinal GISTs being more clinically aggressive compared to gastric GISTs. 18, 19 Although this clinical observation has been correlated with distinct gene expression profiles between gastric and intestinal GISTs, 20 it remains unclear whether this difference is already determined before neoplastic transformation, or is the consequence of a discrete genetic evolution of gastric and intestinal GISTs. GIST tumor cells are dependent on oncogenic KIT or PDGFRA signaling, permitting increased ligand-independent cell proliferation. 4 Although secondary genetic events are doubtless involved in acceleration of malignant potential in GISTs, it is likely that the simple expression and activation level of KIT and PDGFRA at least initially controls the intensity of intracellular signal transduction, and, through the balance between cell proliferation and cell survival, the biological tumor behavior. Whereas the previously described mutation-dependent regulation of KIT and PDGFRA expression might account for the less aggressive clinical behavior of GISTs with PDGFRA mutation, 11 the Site-dependent KIT and PDGFRA expression F Haller et al current finding of a site-dependent regulation of KIT and PDGFRA expression provides a reason for the less aggressive clinical behavior of gastric GISTs. 18 The current study cannot clarify whether KIT and PDGFRA influence each others' expression reciprocally or are regulated independently. Assuming the latter model, our finding would argue for a derivation of gastric and intestinal GISTs from distinct types of precursor cells, as has already been formulated by Nishitani et al. 27 To date, the interstitial cells of Cajal located in the muscular layer of the gastrointestinal tract are regarded as the precursor cell for GISTs. Light and electron microscopy studies have demonstrated that there are morphologically distinguishable types of interstitial cells of Cajal with a site-specific distribution in the gastrointestinal tract. 28 An immunohistochemical analysis revealed that not all interstitial cells of Cajal in the human gut expressed KIT. 29 The same authors reported that blocking of KIT signaling in newborn mice resulted in the almost complete disappearance Site-dependent KIT and PDGFRA expression F Haller et al of interstitial cells of Cajal, while the remaining undifferentiated precursor cells developed an ultrastructural smooth muscle cell phenotype. 30 Thus a subset of interstitial cells of Cajal seems to be dependent on KIT signaling for the maintenance of their specific phenotype, while the role of PDGFRA signaling in these cells remains to be investigated. Taken together, a dependency of different interstitial cells of Cajal in the human gut on KIT or PDGFRA expression and signaling for maintenance of functionality is likely, and would explain the observed site-dependent differences in the expression of KIT and PDGFRA.
